Hesperos Technology Featured on NIH Director’s BLog: Body-on-a-Chip Device Predicts Cancer Drug Responses We are proud to announce our latest papers has been featured on the director’s blog of the The National Institutes of Health. In … Read More
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful … Read More
Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the “human-on-a-chip” in vitro system has announced the use of its innovative multi-organ model to successfully measure the … Read More
In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to inform treatment decisions. ORLANDO, FLA – June 19, 2019 — A reconfigurable “body-on-a-chip” model could transform drug development … Read More
The interest in our human-on-a-chip model continues to grow. Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live … Read More
Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals as test subjects is one step closer to reality with … Read More
We’ve been forging new frontiers with our human-on-a-chip multi-organ models—could the next one take us into space? Last month, we traveled to Washington, DC, to attend a workshop with officials from NASA,NCATS (National Center for Advancing … Read More